<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018602</url>
  </required_header>
  <id_info>
    <org_study_id>808040006</org_study_id>
    <nct_id>NCT01018602</nct_id>
  </id_info>
  <brief_title>PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, 2-arm Controlled Study to Evaluate Efficacy of the DPPIV-inhibitor Vildagliptin for Prevention of Type 2 Diabetes in Women With a Recent History of Insulin-requiring Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut fur Diabetesforschung, Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut fur Diabetesforschung, Munich, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to prove the efficacy of the oral intake of vildagliptin in a daily
      dose of 100 mg in scope of the development of type 2 diabetes in women with insulin dependent
      gestational diabetes in their last pregnancy not longer than 9 months after birth.

      In this randomized, placebo-controlled, double-blinded clinical phase II study, 140
      participants aged 18 years or older and an insulin dependent gestational diabetes in their
      last pregnancy should be included and treated with vildagliptin or placebo over 24 months,
      followed by a 12 months observation period. Exclusion criteria are pregnancy and lactation as
      well as a clinical overt diabetes or islet autoimmunity.

      The null hypothesis is that there is no significant difference of diabetes incidence
      (according to ADA criteria 1997) in both groups.

      Primary endpoint is the clinical manifestation of diabetes, secondary endpoints include the
      improvement of beta cell function (evaluable by C-peptide measurement) and of insulin
      sensitivity by the treatment with vildagliptin.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>development of type 2 diabetes mellitus by criteria of ADA 1997</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Insulin-dependent Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>vildagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>inactive pill without active agent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>participants receive an inactive pill without active agent, but undergo the same examinations, visits and tests as the group treated with vildagliptin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <description>100 mg per day over 24 months</description>
    <arm_group_label>vildagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>inactive pill</intervention_name>
    <description>1 pill per day over 24 months</description>
    <arm_group_label>inactive pill without active agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with insulin-dependent gestational diabetes during the last pregnancy

          -  &lt; 9 months after delivery

          -  age 18 years or older

          -  contraception during intervention period (at least 24 months)

        Exclusion Criteria:

          -  pregnancy or lactation

          -  GADA or IA-2A positivity

          -  clinical overt diabetes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anette G Ziegler, MD</last_name>
    <phone>+49 (0)89 3068 2917</phone>
    <phone_ext>2917</phone_ext>
    <email>anziegler@lrz.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut fuer Diabetesforschung</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anette G Ziegler, MD</last_name>
      <phone>+49 (0)89 3068 2917</phone>
      <phone_ext>2917</phone_ext>
      <email>anziegler@lrz.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Anette G Ziegler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>June 24, 2011</last_update_submitted>
  <last_update_submitted_qc>June 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Anette-G. Ziegler</name_title>
    <organization>Institut fur Diabetesforschung, Munich, Germany</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

